The recent fall of the market is largely triggered by IT and pharma stocks. Together, these sectors represent ~15% of the broader Indian market. The IT index came under early pressure amid concerns over rising H-1B visa costs and Accenture’s recent subdued outlook, while fresh 100% U.S. tariffs on pharma products triggered heavy selling in the sector. Mid- and small-cap stocks fell more steeply than large caps, reflecting valuation pressures. Also Read | How will US tariffs impact India's GDP growth? LGT Wealth's Lokapriya explains

The proposed 100% US tariffs on branded and patented pharmaceutical products are expected to affect manufacturing facilities in South Korea, the UK, Ireland, and Switzerland, although countries with US trade agreements, like the UK, the EU, and Japan,

See Full Page